<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315182</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-002</org_study_id>
    <nct_id>NCT03315182</nct_id>
  </id_info>
  <brief_title>Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB</brief_title>
  <acronym>MPSIIIB</acronym>
  <official_title>Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abeona Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abeona Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, dose-escalation clinical trial of rAAV9.CMV.hNAGLU injected intravenously through
      a peripheral limb vein
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV
      enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter
      inserted into a peripheral limb vein. A tapering course of prophylactic enteral prednisone or
      prednisolone will be administered for a period of at least two months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Age Equivalent Developmental score (calculated by the Mullen Scales of Early Learning or the Kaufman Assessment Battery for Children Second Edition, based on developmental age) compared with Natural History Study data</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Product safety as defined by the incidence, type and severity of treatment-related adverse events and serious adverse events</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of central spinal fluid heparan sulfate after treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of plasma or urine glycosaminoglycans or heparan sulfate after treatment</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CSF or plasma NAGLU enzyme activity levels after treatment</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver and/or spleen volumes after treatment, as measured by magnetic resonance imaging</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in brain volumes after treatment, as measured by magnetic resonance imaging</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Cognitive Age Equivalent (Developmental Age) compared to Natural History Study, calculated using the Bayley Scales of Infant and Toddler Development or the Kaufman Assessment Battery for Children</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Adaptive Age Equivalent score after treatment compared to Natural History Study data, as assessed by parent report using the Vineland Adaptive Behavior Scale II Survey form</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Developmental Quotient after treatment compared to Natural History Study data assessed by the Mullen Scales of Early Learning or the Kaufman Assessment Battery for Children.</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pediatric Quality of Life Inventory (PedsQL™) Generic Core Scales total score</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in parent quality of life, using the Parenting Stress Index, 4th Edition (PSI-4) short form</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of vector shedding analysis in plasma, saliva, urine and feces will provide preliminary data for the Environmental Risk Assessment</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mucopolysaccharidosis Type 3 B</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion:
• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion:
• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (High Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single infusion:
• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV9.CMV.hNAGLU</intervention_name>
    <description>Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.</description>
    <arm_group_label>Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_label>Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU</arm_group_label>
    <arm_group_label>Cohort 3 (High Dose) rAAV9.CMV.hNAGLU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of MPSIIIB by both of the following two methods:

               -  No detectable or significantly reduced NAGLU enzyme activity by plasma.

               -  Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations
                  in the NAGLU gene

          -  Age: From Birth to 2 years or children older than 2 years with a minimum cognitive
             Development Quotient (DQ) of 60 or above (calculated by Bayley Scales of Infant and
             Toddler Development - Third Edition)

        Exclusion Criteria:

          -  Inability to participate in the clinical evaluation as determined by Principal
             Investigator

          -  Identification of two nonsense or null variants on genetic testing of the NAGLU gene

          -  Has evidence of an attenuated phenotype of MPS IIIB

          -  Presence of a concomitant medical condition that precludes lumbar puncture or use of
             anesthetics

          -  Active viral infection based on clinical observations as infections by Adenoviruses,
             Epstein-Barr Virus, Cytomegalovirus, Respiratory Syncytial Virus

          -  Concomitant illness or requirement for chronic drug treatment that in the opinion of
             the PI creates unnecessary risks for gene transfer , or precludes the child from
             participating in the protocol assessments and follow up as autoimmune diseases
             requiring immunosuppression, such as juvenile rheumatoid arthritis or idiopathic
             thrombocytopenia purpura

          -  Subjects with total anti-AAV9 antibody titers ≥ 1:100 as determined by ELISA binding
             immunoassay

          -  Subjects with a positive response for the ELISPOT for T-cell responses to AAV9

          -  Serology consistent with exposure to HIV, or serology consistent with active hepatitis
             B or C infection

          -  Bleeding disorder or any other medical condition or circumstance in which a lumbar
             puncture (for collection of CSF) is contraindicated according to local institutional
             policy

          -  Visual or hearing impairment sufficient to preclude cooperation with
             neurodevelopmental testing

          -  Uncontrolled seizure disorder

          -  Any item (braces, etc.) which would exclude the subject from being able to undergo MRI
             according to local institutional policy

          -  Any other situation that precludes the subject from undergoing procedures required in
             this study

          -  Subjects with cardiomyopathy or significant congenital heart abnormalities

          -  The presence of significant non-MPS IlIB related CNS impairment or behavioral
             disturbances that would confound the scientific rigor or interpretation of results of
             the study

          -  Abnormal laboratory values Grade 2 or higher as defined in CTCAE v4.0 for GGT, total
             bilirubin, creatinine, hemoglobin, WBC count, platelet count, PT and aPTT

          -  Female participant who is pregnant or demonstrates a positive urine or serum result at
             screening assessment (if applicable).

          -  Any vaccination with viral attenuated vaccines less than 30 days prior to the
             scheduled date of treatment (and use of prednisolone)

          -  Previous treatment by Haematopoietic Stem Cell transplantation

          -  Previous participation in a gene/cell therapy or ERT clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Affairs</last_name>
    <phone>+1 646 813 4701</phone>
    <email>sanfilippo@abeonatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Brown</last_name>
      <phone>614-722-6918</phone>
      <email>kristen.brown@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Tabatha Simmons, PhD</last_name>
      <phone>614-722-6921</phone>
      <email>tabatha.simmons@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Armand-Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte Héron, MD</last_name>
      <phone>+33 (0)1 44 73 74 30</phone>
      <email>benedicte.heron@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Revelli, MD</last_name>
      <email>claudia.ravelli@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Maria Muschol, MD</last_name>
      <email>muschol@uke.de</email>
    </contact>
    <investigator>
      <last_name>Nicole Maria Muschol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Luz Couce, MD</last_name>
      <phone>+34 981 950 151</phone>
      <email>maria.luz.couce.pico@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Maria Jose de Castro, MD</last_name>
      <phone>+34 981 955 627</phone>
      <email>maria.jose.de.castro.lopez@sergas.es</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Luz Couce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fu H, Dirosario J, Killedar S, Zaraspe K, McCarty DM. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther. 2011 Jun;19(6):1025-33. doi: 10.1038/mt.2011.34. Epub 2011 Mar 8.</citation>
    <PMID>21386820</PMID>
  </reference>
  <reference>
    <citation>Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov;119(3):239-248. doi: 10.1016/j.ymgme.2016.08.002. Epub 2016 Aug 18.</citation>
    <PMID>27590925</PMID>
  </reference>
  <reference>
    <citation>Neufeld EF, Cantz MJ. Corrective factors for inborn errors of mucopolysaccharide metabolism. Ann N Y Acad Sci. 1971 Jul 6;179:580-7.</citation>
    <PMID>4255108</PMID>
  </reference>
  <reference>
    <citation>Weber B, Guo XH, Kleijer WJ, van de Kamp JJ, Poorthuis BJ, Hopwood JJ. Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet. 1999 Jan;7(1):34-44.</citation>
    <PMID>10094189</PMID>
  </reference>
  <reference>
    <citation>Wijburg FA, Węgrzyn G, Burton BK, Tylki-Szymańska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr. 2013 May;102(5):462-70. doi: 10.1111/apa.12169. Epub 2013 Feb 6. Review.</citation>
    <PMID>23336697</PMID>
  </reference>
  <reference>
    <citation>de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr Pharm Biotechnol. 2011 Jun;12(6):923-30. doi: 1389-2010/11 $58.00+.00. Review.</citation>
    <PMID>21235449</PMID>
  </reference>
  <reference>
    <citation>Murrey DA, Naughton BJ, Duncan FJ, Meadows AS, Ware TA, Campbell KJ, Bremer WG, Walker CM, Goodchild L, Bolon B, La Perle K, Flanigan KM, McBride KL, McCarty DM, Fu H. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates. Hum Gene Ther Clin Dev. 2014 Jun;25(2):72-84. doi: 10.1089/humc.2013.208. Epub 2014 Apr 10.</citation>
    <PMID>24720466</PMID>
  </reference>
  <reference>
    <citation>Ribera A, Haurigot V, Garcia M, Marcó S, Motas S, Villacampa P, Maggioni L, León X, Molas M, Sánchez V, Muñoz S, Leborgne C, Moll X, Pumarola M, Mingozzi F, Ruberte J, Añor S, Bosch F. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum Mol Genet. 2015 Apr 1;24(7):2078-95. doi: 10.1093/hmg/ddu727. Epub 2014 Dec 18.</citation>
    <PMID>25524704</PMID>
  </reference>
  <reference>
    <citation>Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol. 2008 May;115(5):547-59. Epub 2007 Dec 4.</citation>
    <PMID>18060551</PMID>
  </reference>
  <reference>
    <citation>Tamagawa K, Morimatsu Y, Fujisawa K, Hara A, Taketomi T. Neuropathological study and chemico-pathological correlation in sibling cases of Sanfilippo syndrome type B. Brain Dev. 1985;7(6):599-609.</citation>
    <PMID>3938624</PMID>
  </reference>
  <reference>
    <citation>Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2011 Aug;11(4):321-30. Review.</citation>
    <PMID>21557723</PMID>
  </reference>
  <reference>
    <citation>Saeki I, Tokunaga S, Matsuura T, Hayashida M, Yanagi Y, Taguchi T. A formula for determining the standard liver volume in children: a special reference for neonates and infants. Pediatr Transplant. 2012 May;16(3):244-9. doi: 10.1111/j.1399-3046.2011.01624.x. Epub 2011 Dec 12.</citation>
    <PMID>22151603</PMID>
  </reference>
  <reference>
    <citation>Schlesinger AE, Edgar KA, Boxer LA. Volume of the spleen in children as measured on CT scans: normal standards as a function of body weight. AJR Am J Roentgenol. 1993 May;160(5):1107-9.</citation>
    <PMID>8470587</PMID>
  </reference>
  <reference>
    <citation>Malm G, Månsson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr. 2010 Aug;99(8):1253-7. doi: 10.1111/j.1651-2227.2010.01800.x. Epub 2010 Mar 14.</citation>
    <PMID>20337777</PMID>
  </reference>
  <reference>
    <citation>Dale DC, Fauci AS, Guerry D IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975 Oct;56(4):808-13.</citation>
    <PMID>1159089</PMID>
  </reference>
  <reference>
    <citation>Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010 Aug;31(8):318-24. doi: 10.1016/j.it.2010.05.006. Review.</citation>
    <PMID>20620114</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS IIIB</keyword>
  <keyword>Sanfilippo Syndrome B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

